Phase i trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma

Daruka Mahadevan, Donald W. Northfelt, Pavani Chalasani, Diane Rensvold, Sandra Kurtin, Daniel D. Von Hoff, Mitesh J. Borad, Raoul Tibes

Resultado de la investigación: Articlerevisión exhaustiva

17 Citas (Scopus)


Objectives: UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. A Phase I study of UNBS5162 was conducted to establish pharmacokinetics (PK), maximum tolerated dose (MTD), dose-limiting toxicity, safety and anti-tumor activity in patients with advanced solid tumors or lymphoma. Methods: UNBS5162 was administered in a 3 + 3 dose escalation scheme by intravenous infusion over 1 h weekly for 3 weeks of a 4-week cycle. Safety, serial serum PK and tolerability were captured throughout the study. Response Evaluation Criteria in Solid Tumors was utilized every 2 cycles to assess for anti-tumor response. Results: Twenty-four patients with metastatic carcinoma and 1 patient with lymphoma were treated at eight dose levels (18-234 mg/m2). All patients were evaluable for tolerability and toxicity. Grade 3 toxicities include nausea (n = 1), fatigue (n = 1) and anorexia (n = 1). Prolongation of QTc [Hodges] was observed in 6 cases (Gr 1 = 2; Gr 2 = 2; Gr 3 = 2). C max and area under the curve increased linearly with dose with a t 1/2 of 30-60 min. 16 patients completed 2 cycles of therapy, all with pharmacodynamics at 8 weeks. Conclusions: The MTD or dose-limiting toxicity for UNBS5162 was not reached due to the magnitude of QTc prolongation at the highest dose of 234 mg/m2/week that led to study termination.

Idioma originalEnglish (US)
Páginas (desde-hasta)934-941
Número de páginas8
PublicaciónInternational Journal of Clinical Oncology
EstadoPublished - oct 2013
Publicado de forma externa

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology


Profundice en los temas de investigación de 'Phase i trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma'. En conjunto forman una huella única.

Citar esto